Antibody/Targeted-Drug Conjugates 2019

6-8 November 2019, Queen’s University Belfast, Belfast, Northern Ireland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 6th November 2019

08.30 onwards
Registration

09.50-10.10
Welcome & Opening Remarks

ATDC 2019 Chairman Chris Scott
(The Queen’s University Belfast, Belfast, Northern Ireland, UK)

SESSION 1:
OPENING PLENARY SESSION

Moderator: Chris Scott
(The Queen’s University Belfast, Belfast, Northern Ireland, UK)

10.00-11.00
KEYNOTE
‘Site-specific conjugation in ADC design: Panacea or hype/ Lessons from a case study with a maytansinoid conjugate’

John Lambert
(Attager Consulting/The Queen’s University Belfast, Belfast, Northern Ireland, UK)

11.00-11.30
Coffee Break

SESSION 2:

Moderator: Chris Scott
(The Queen’s University Belfast, Belfast, Northern Ireland, UK)

11.30-12.00
‘NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer’

Roger Beerli
(NBE Therapeutics Ltd, Basel, Switzerland)

12.00-12.30
‘Exploiting a drug discovery platform based on engineered VNAR domains for the development of novel protein drug conjugates targeting ROR1’

Graham Cotton
(Almac Discovery, Edinburgh, Scotland, UK)

12.30-13.00
‘Formation of homogenous antibody-conjugates through pyridazinedione re-bridging of native IgG disulfide bonds’
Calise Bahou1,2, Elizabeth A. Love2, James R. Baker1 and Vijay Chudasama1,3
(1 Department of Chemistry, University College London, London; 2 LifeArc, SBC Open Innovation Campus, Stevenage, UK; 3 Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal)

13.00-13.15
Moderator-led Discussion

13.15-14.15
Lunch Break

SESSION 3:
CANCER

Moderator: Victor Goldmacher
(Forbius (Formation Biologics), Inc., USA)

14.15-14.45
‘Development of an EFGR targeted ADC for pancreatic cancer’

Michelle Green
(Queen’s University Belfast, Belfast, Northern Ireland, UK)

14.45-15.15
‘DR5 targeted nanosystems for the treatment of drug resistant pancreatic cancer’

Michael Johnston
(Queen’s University Belfast, Belfast, Northern Ireland, UK)

15.15.15.45
‘PMSA targeted drugs for prostate cancer’

Aidan Cole
(Queen’s University Belfast, Belfast, Northern Ireland, UK)

15.45-16.00
Moderator Led Discussion

16.00-16.30
Tea Break

 

ATDC 2019 Delegates

Login details will be supplied after you have registered for the event.


ATDC 2019 Sponsors

  • ONdrugDELIVERY
  • Genentech
  • OncoZine
  • Lonza
  • NBE Therapeutics
  • LinXis
  • Cancer Targeting Solutions Consulting
  • Genovis
  • NatureGeneTherapy.com
  • Aldevron
  • ADC Review
  • Almac Discovery
  • ImmunoGen
  • Sutro Biopharma
  • Catalent Biologics

ATDC 2019 Downloads

ATDC 2019 Leaflet

ATDC 2019 Mailing List

Name
E-mail Address
What is 3+2-1?